Resources

Filter by:

A bispecific nanobody for the treatment of von Willebrand disease type 1

Peyron I, Casari C, McCluskey G, Licari V, Bocquet E, Auditeau C, Daniel MY, Roullet S, Susen S, Christophe OD, Lenting PJ, & Denis CV

Effect of age on ISTH-BAT scores and low VWF diagnosis in the Zimmerman Program

Atiq F, Christopherson PA, Doherty D, Hulshof AM, Haberichter SL, Flood VH, Lavin M, O’Connell NM, Ryan K, Byrne M, Grabell J, James PD, Lillicrap D, Montgomery RR, Di Paola J, & O’Donnell JS

Genetic study of von Willebrand factor antigen levels ≤ 50 IU/dL identifies variants associated with increased risk of von Willebrand disease and bleeding

Friedman RK, Heath AS, Huffman JE, Baker JT, Hasbani NR, Gagliano Taliun SA, Chen MH, Howard TE, Lewis JP, Pankratz N, Patil S, Reiner AP, Thibord F, Yanek LR,Jie Yao J, et al.

Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF

Atiq F, Blok R, van Kwawegen CB, Hulshof AM, Doherty D, Lavin M, van der Bom JG, O’Connell NM, de Meris J, Ryan K, Schols SEM, van Heerde WL, Doyle M, Byrne M, Heubel-Moenen FCJI, van Galen KPM, Preston RJS, Cnossen MH, Fijmvamdraat K, Baker RI, Meijer K, James P, Di Paola J, Eikenboom J, Leebeek FWG, & O’Donnell JS